These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31603996)

  • 1. Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Bastin S; Gamble GD
    J Bone Miner Res; 2020 Jan; 35(1):20-27. PubMed ID: 31603996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    J Intern Med; 2019 Aug; 286(2):221-229. PubMed ID: 30887607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
    Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
    Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women.
    Reid IR; Bastin S; Horne AM; Mihov B; Gamble GD; Bolland MJ
    J Bone Miner Res; 2022 Nov; 37(11):2149-2155. PubMed ID: 36053844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.
    Grey A; Horne A; Gamble G; Mihov B; Reid IR; Bolland M
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32016386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate.
    Reid IR; Horne AM; Mihov B; Stewart A; Bolland MJ; Bastin S; Gamble GD
    J Bone Miner Res; 2021 Jan; 36(1):61-66. PubMed ID: 32835417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.
    Reid IR; Horne AM; Mihov B; Stewart A; Bastin S; Gamble GD
    Calcif Tissue Int; 2020 Apr; 106(4):386-391. PubMed ID: 31897528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.
    Patel DV; Bolland M; Nisa Z; Al-Abuwsi F; Singh M; Horne A; Reid IR; McGhee CN
    Osteoporos Int; 2015 Feb; 26(2):499-503. PubMed ID: 25187119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial.
    Reid IR; Horne AM; Mihov B; Stewart A; Bastin S; Gamble GD
    Calcif Tissue Int; 2021 Jul; 109(1):12-16. PubMed ID: 33712919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
    Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
    Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.